Close Menu

NEW YORK – Clinical biomarker services firm Targos Molecular Pathology said today that it has formed a partnership with Cambridge, Massachusetts-based Ultivue to provide standardized multiplex phenotypic assays to pharmaceutical companies for the characterization of samples selected for clinical research programs.

Ultivue's UltiMapper assays are used in tumor immune-profiling research strategies by the biomedical community to demonstrate the clinical utility of panels of markers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.